- Home
- MBRX vs INAB Comparison
MBRX vs INAB Comparison
Compare MBRX & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBRX | INAB |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.5M | 10.6M |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MBRX | INAB |
|---|---|---|
| Price | $4.90 | $1.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $105.50 | ★ $108.00 |
| AVG Volume (30 Days) | ★ 296.9K | 51.5K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.75 | $1.53 |
| 52 Week High | $91.25 | $12.53 |
Technical Indicators
Market Signals| Indicator | MBRX | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 61.39 | 42.30 |
| Support Level | $4.75 | $1.73 |
| Resistance Level | $7.98 | $1.80 |
| Average True Range (ATR) | 0.59 | 0.13 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 60.11 | 2.28 |
Price Performance
Historical ComparisonAbout MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.